Fresenius traded at 43.90 this Thursday March 26th, decreasing 0.61 or 1.37 percent since the previous trading session. Looking back, over the last four weeks, Fresenius lost 13.75 percent. Over the last 12 months, its price rose by 9.75 percent. Looking ahead, we forecast Fresenius to be priced at 42.80 by the end of this quarter and at 39.16 in one year, according to Trading Economics global macro models projections and analysts expectations.
Fresenius SE & Co KGaA is a Germany-based healthcare group. It operates through four business segments. Fresenius Medical Care runs a global network of dialysis clinics, providing treatment for patients with chronic kidney failure. It also offers dialyzers, dialysis machines and renal pharmaceuticals. Fresenius Kabi specializes in intravenously administered generic drugs (IV drugs), clinical nutrition and infusion therapies. It also supplies hospitals with medical devices and products of transfusion technology. Fresenius Helios is a private hospital operator, with over 130 facilities in Germany, including maximum care hospitals and rehabilitation centers and, through Quironsalud, over 80 hospitals and outpatient centers, as well as approximately 300 Occupational Risk Prevention Centers in Spain. Fresenius Vamed manages projects and provides services for health care facilities worldwide, from development and turnkey construction to maintenance and total operational management.